Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01686607 · ClinicalTrials.gov registry record
Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents
A clinical trial of Systemic Fungal Infections, sponsored by Astellas Pharma Europe B.V..
- Completed
- Registry status
- 40,110
- Enrollment target
- 6
- Study locations
NCT01686607: Completed study of Systemic Fungal Infections, sponsored by Astellas Pharma Europe B.V..
NCT01686607 is a study of Systemic Fungal Infections that has completed, run by Astellas Pharma Europe B.V.. The registered enrollment target is 40,110 participants. The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01686607, a study of Systemic Fungal Infections, has completed, sponsored by Astellas Pharma Europe B.V..
- COMPLETED
- Registry status
- 40,110 participants
- Enrollment target
- 6
- Study locations
Study Summary
This multicenter observational cohort study proposes to establish the risks of short and long-term outcomes in users of parenteral micafungin and in users of other parenteral antifungal agents from 2005 through 2012 with follow-up until 2017.
Primary Outcome
Data will be used of patients treated during the years 2005-2012 with a parenteral antifungal agent in the participating centers.
Conditions Studied
Interventions
- DRUG Parenteral micafungin application
- DRUG Other parenteral antifungal drugs
Study Locations (6)
Pennsylvania
- Site US5 - Philadelphia
- Site US1 - Pittsburgh
Maryland
- Site US4 - Baltimore
Massachusetts
- Site US2 - Boston
Michigan
- Site US6 - Ann Arbor
North Carolina
- Site US3 - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40,110 participants |
| Start Date | 2012-10-01 |
| Est. Completion | 2018-04-30 |
What the finished NCT01686607 record still lists
NCT01686607 is an observational study that tracks outcomes without assigning an intervention. Its 40,110 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with Systemic Fungal Infections appearing as the primary indexed condition, and to 2 interventions - of which Parenteral micafungin application is the first listed.
NCT01686607 lists 6 locations in 5 states (Pennsylvania, Maryland, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT01686607 about?
NCT01686607 is a clinical study titled "Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents". This multicenter observational cohort study proposes to establish the risks of short and long-term outcomes in users of parenteral micafungin and in users of other parenteral antifungal agents from 2005 through 2012 with follow-up until 2017.
What is the current status of trial NCT01686607?
This trial is currently completed. The enrollment target is 40,110 participants. The study started on 2012-10-01. Estimated completion is 2018-04-30.
What conditions does trial NCT01686607 study?
This clinical trial studies the following conditions: Systemic Fungal Infections.
What interventions are being tested in trial NCT01686607?
The interventions under investigation include: Parenteral micafungin application (DRUG), Other parenteral antifungal drugs (DRUG).
Who is sponsoring clinical trial NCT01686607?
This trial is sponsored by Astellas Pharma Europe B.V., which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01686607 being conducted?
This trial has 6 study locations across Maryland, Massachusetts, Michigan, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01255748 · 40,000 participants
Registry Study for Radiation Therapy Outcomes
- NCT04994756 · 40,000 participants
Stroke Thrombectomy and Aneurysm Registry
- NCT06768814 · 40,000 participants · NA
Overdose Recovery and Care Access (ORCA) Qualitative Stakeholder Interviews and County-level Data
- NCT07109427 · 40,000 participants · NA
Impact of an Electronic Health Record Maintenance Alert on PSA Screening Rates in a 10-Hospital Integrated Health System
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI